CAR T-cell Therapy for Multiple Myeloma

CAR T-cell Therapy is a new treatment option for patients with multiple myeloma. Is it right for you?

Printer-friendly versionPDF version Registration Coming Soon
Wednesday, September 22, 2021


CAR T-Cell Therapy for Patients with Multiple Myeloma

Wednesday, September 22, 2021 

Time:   7:00 pm Eastern,  6:00 pm Central,  5:00 pm Mountain,  4:00 pm Pacific

Duration:  40 minutes followed by questions and answers

Presenter: David Vesole MD, PhD, FACPDirector of the Myeloma Program at Medstar Georgetown University Hospital, and Director of the Myeloma Division and Director of Myeloma Research at The John Theurer Cancer Center at Hackensack Meridian School of Medicine.

Multiple myeloma is a cancer of plasma cells - cells in the bone marrow that are an important part of the immune system. When plasma cells become cancerous, they replicate uncontrollably and make it difficult for the bone marrow to produce normal red blood cells, white blood cells and platelets. Multiple myeloma can cause bone pain or fractures, shortness of breath, serious bleeding and increased infections.

Approximately 35,000 new cases of multiple myeloma are diagnosed in the U.S. each year. Depending on the stage of the disease, treatment can range from "watchful waiting" to a stem cell transplant with follow-up maintenance therapy.

A new therapy has emerged for patients with multiple myeloma:  CAR T-Cell therapy. 

In this webinar you will learn:

  • who is a candidate for CAR T-cell Therapy
  • steps involved in undergoing CAR T-cell therapy
  • potential risks and side effects
  • how outcomes after CAR T-cell therapy compare to other treatment options such as stem cell transplantation

Bring your questions!

The webinar is free, but advance registration is required.  All you will need to participate is a computer, smart phone or other electronic device.

About the Speaker 

Dr. David H. Vesole, MD, PhD is Director,  Myeloma Program at MedStar Georgetown University Hospital and a Professor of Medicine at Georgetown University. Concurrently, he is Co-Director of the Myeloma Division and Director of Myeloma Research at the John Theurer Cancer Center at Hackensack Meridian School of Medicine where is also a Professor of Medicine. 

A nationally recognized expert in multiple myeloma, Dr. Vesole is active in several professional organizations including the American Society for Transplantation and Cellular Therapy, the American Society of Clinical Oncology and the American Society of Hematology. He previously served as co-chair of the Eastern Cooperative Oncology Group Myeloma Committee and the Center for International Blood and Marrow Transplant Research (CIBMTR) Plasma Cell Disorder Committee and a board member of the New York City chapter of the Leukemia and Lymphoma Society. He is an inspector for the Foundation for the Accreditation of Cellular Therapy (FACT) and a member of the International Myeloma Working Group.

Dr. Vesole has authored more than 250 articles in peer-reviewed medical journals and over 20 book chapters. He serves as a reviewer for several journals, including the American Journal of Hematology, Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplant, Bone Marrow Transplant, Leukemia, Leukemia and Lymphoma and Clinical Lymphoma Myeloma & Leukemia. Dr. Vesole has presented his research at medical meetings and symposia nationally and internationally.

Many thanks to Bristol Meyer Squibb and Sanofi US for their unrestricted educational grants in support of this webinar